Retatrutide Research Guide

Metabolic research peptide

Retatrutide is a triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. In a Phase 2 trial published in the New England Journal of Medicine, the highest dose produced a mean body-weight reduction of 24.2% at 48 weeks — the largest weight-loss effect ever reported for a single pharmacological agent in this class.

GLP-1 / GIP / Glucagon Triple agonist

~6 days Plasma half-life

Weekly Dosing cadence

What is Retatrutide?

Retatrutide, internally designated LY3437943 by its developer Eli Lilly, is a synthetic 39-amino-acid peptide engineered to bind three metabolic receptors at once: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This triple-incretin profile distinguishes it from earlier metabolic peptides like semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP).

Within metabolic research circles it is studied as the most potent member of the incretin-mimetic class, with publicly reported Phase 2 data showing weight-loss magnitudes that exceed every previous reference compound. It is currently in Phase 3 clinical investigation for obesity and type-2 diabetes endpoints, with additional studies underway in metabolic-associated steatohepatitis (MASH) and obstructive sleep apnea.

For in vitro and animal research, Retatrutide is supplied as a lyophilized powder, typically in 10 mg or 20 mg vials. Each Aeternum Labs batch is verified to 99%+ purity by mass spectrometry and HPLC, with a batch-specific Certificate of Analysis published in the public COA library.

Mechanism of action

The GLP-1 receptor arm drives glucose-dependent insulin secretion from pancreatic beta cells, slows gastric emptying, and reduces appetite signaling at the hypothalamus. This is the same mechanism leveraged by semaglutide and liraglutide in the GLP-1 monoagonist class.

The GIP receptor arm enhances insulin secretion under hyperglycemic conditions and modulates adipose tissue function. There is active debate in the literature about whether GIP agonism or antagonism produces better metabolic outcomes, but Retatrutide’s design takes the agonist path and pairs it with the other two receptors.

The glucagon receptor arm is the differentiating element. Glucagon agonism increases hepatic glucose output (a counterproductive effect for diabetes management on its own), but it also drives lipolysis in adipose tissue and increases resting energy expenditure. When balanced against the simultaneous GLP-1 insulinotropic effect, the net outcome in published trials is enhanced fat loss without the glycemic deterioration glucagon agonism alone would produce.

The molecular structure is a modified form of the native GIP backbone with substitutions that confer activity at all three receptors and extend the plasma half-life through fatty-acid acylation, similar to the design strategy used for semaglutide.

Research history

Retatrutide was first disclosed in Eli Lilly research publications around 2022, with early preclinical pharmacology data establishing its triple-receptor activity profile. The first widely-cited human data came from Jastreboff et al. (2023) published in the New England Journal of Medicine, reporting Phase 2 obesity results that immediately reframed expectations for the entire incretin class.

The Jastreboff 48-week data showed mean weight reductions of 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), and 24.2% (12 mg) in adult participants with obesity. For context, semaglutide 2.4 mg (the highest approved obesity dose at the time) produced approximately 14.9% mean weight reduction over 68 weeks in the STEP-1 trial. Retatrutide produced higher reductions in less than three quarters of that timeframe.

Phase 3 trials are now in progress under the TRIUMPH program, evaluating obesity, type-2 diabetes, and related metabolic endpoints. Results from these trials will determine the regulatory trajectory of the compound and the eventual labeled indications, if any.

Half-life and pharmacokinetics

Retatrutide has a reported plasma elimination half-life of approximately 144 hours (six days), supporting once-weekly subcutaneous administration in human research. The extended half-life is a deliberate consequence of the C-20 fatty-acid acylation in the molecule, which promotes reversible binding to serum albumin and slows renal and proteolytic clearance.

Time to maximum plasma concentration (Tmax) after subcutaneous administration is approximately 24–72 hours, with steady-state typically reached after four to six weekly doses. The pharmacokinetic profile is dose-proportional across the studied range.

Typical research doses

Reported dose ranges in published Phase 2 obesity research span 0.5 mg to 12 mg administered weekly via subcutaneous injection, with titration schedules used to manage gastrointestinal tolerability. Published titration patterns escalate from 2 mg weekly for the first four weeks, then 4 mg, 8 mg, and 12 mg in successive monthly increments.

In the type-2 diabetes Phase 2 trial reported by Rosenstock et al. (2023), doses ranged from 0.5 mg to 12 mg weekly, with HbA1c reductions and weight-loss magnitudes scaling with dose.

For in vitro receptor binding studies and animal model work, dose ranges are highly variable depending on the species and the specific endpoint being measured. Dose calculation in research protocols should always reference the published source paper for the specific endpoint of interest.

Reconstitution protocol

Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.

Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.

Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.

For Retatrutide specifically, a 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. Each 0.1 mL contains 0.5 mg, giving researchers fine-grained dose titration capability across the published 0.5–12 mg range.

Storage and stability

Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.

Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.

Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.

Common stack pairings

Retatrutide + Tesamorelin (metabolic + body composition research)

Tesamorelin is a GHRH analogue that targets visceral adipose tissue specifically. When studied alongside Retatrutide’s triple-receptor metabolic activity, the combination is researched for body composition endpoints where total fat mass reduction and visceral-fat-specific reduction are both of interest.

Retatrutide + low-dose Semax (cognitive arm)

Semax is a heptapeptide nootropic with documented effects on BDNF expression in animal research. Studies pairing metabolic compounds with cognitive-enhancement agents typically use Semax as a low-dose addition to capture potential CNS-related secondary endpoints.

How it compares

Compared to semaglutide (GLP-1 monoagonist): Retatrutide’s triple-receptor profile produces approximately 60% higher mean weight reductions in matched-duration trials, at the cost of more pronounced gastrointestinal side effects in the highest dose tiers.

Compared to tirzepatide (GLP-1/GIP dual agonist): the addition of the glucagon arm in Retatrutide drives an additional 5–8 percentage points of weight loss in published Phase 2 data, with somewhat different metabolic shifts (increased energy expenditure being a Retatrutide-specific signal).

Compared to compound classes outside the incretin family (e.g., melanocortin-system agonists like setmelanotide or CB1 antagonists): the incretin class generally shows broader applicability and a more favorable cardiometabolic profile, while specialty agents target narrower populations with specific genetic or physiological substrates.

Frequently asked questions

Is Retatrutide more effective than semaglutide in published research?

In Phase 2 obesity trials, Retatrutide’s highest dose produced approximately 60% greater mean weight reduction than the highest approved semaglutide dose (24.2% vs 14.9%), in a shorter trial duration. Direct head-to-head trials are not yet publicly reported, but the cross-trial comparison consistently favors Retatrutide for total weight-loss magnitude.

Why does Retatrutide include glucagon receptor activity when glucagon raises blood sugar?

Glucagon receptor agonism on its own would worsen glycemic control. The Retatrutide design pairs glucagon with strong GLP-1 insulinotropic activity, which more than compensates for the glucagon-induced hepatic glucose output. The net effect studied in published trials is improved glycemic control along with the metabolic and energy-expenditure benefits unique to glucagon receptor activation.

How is Retatrutide stored before reconstitution?

Sealed lyophilized vials are stored at 0°F (−18°C) for long-term stability up to twenty-four months. Once reconstituted with bacteriostatic water, the working solution is stored at 36–46°F (2–8°C) and used within twenty-eight days.

What dose ranges are reported in the published research?

Published Phase 2 obesity trials use weekly subcutaneous doses ranging from 0.5 mg to 12 mg, with titration schedules to manage gastrointestinal tolerability. Phase 2 type-2 diabetes research uses similar ranges. In vitro and animal research dose ranges vary widely depending on the experimental model and should reference the source paper.

What is Aeternum's purity standard for Retatrutide batches?

Every Aeternum Labs Retatrutide batch is verified to 99%+ purity by HPLC, with mass spectrometry identity confirmation and LAL endotoxin screening. Each batch ships with a publicly published Certificate of Analysis tied to the lot number. The COA library is open to anyone who wants to verify before ordering.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. View source
2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. View source
3. Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. View source
4. Sanyal AJ, Kaplan LM, Frias JP, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. View source
5. Knerr PJ, Mowery SA, Douros JD, et al. (2022). Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. View source

Related research

Category

Best peptides for metabolic research →

Compare

Retatrutide vs Semaglutide →

Pair with

Tesamorelin research guide →

Pair with

MOTS-c research guide →